Immunome Set to Release Q4 2025 Earnings on March 18

Immunome (NASDAQ: IMNM) is poised to announce its financial results for the fourth quarter of 2025 on March 18, 2026, before the market opens. Analysts anticipate the company will report an earnings loss of ($0.64) per share alongside quarterly revenue of $0.785 million. Investors can find further details on the earnings call scheduled for March 3, 2026, at 3:00 PM ET.

In its previous quarter, Immunome reported an earnings loss of ($0.75) per share, which fell short of analysts’ expectations of ($0.65) by $0.10. The company recorded a significant negative return on equity of 57.61% and a staggering negative net margin of 1,687.08%. Looking ahead, analysts predict an average loss of $-2 per share for the current fiscal year and $-3 for the next.

Trading on NASDAQ, Immunome shares opened at $20.36 on Monday. With a market capitalization of $2.30 billion, the company has a price-to-earnings ratio of -8.41 and a beta of 2.12. Over the last twelve months, the stock has fluctuated between a low of $5.15 and a high of $27.65.

Institutional Investors Increase Holdings

Recent trading activity has seen several institutional investors and hedge funds adjust their positions in Immunome. Notably, T. Rowe Price Investment Management Inc. raised its stake by 59.4% in the fourth quarter, acquiring an additional 5,003,824 shares to own a total of 13,421,987 shares valued at approximately $288.3 million.

Additionally, Invesco Ltd. increased its holdings by 382.1%, now owning 270,065 shares worth around $5.8 million. Virtus Investment Advisers LLC raised its stake by 16.9%, now holding 13,593 shares valued at $292,000. Furthermore, Wellington Management Group LLP expanded its ownership by 267.8%, increasing its total to 934,463 shares worth approximately $20.1 million. Currently, institutional investors and hedge funds own 44.58% of Immunome’s stock.

Analysts Adjust Price Targets

Several equity research analysts have recently revised their price targets for Immunome. Evercore raised its target from $18.00 to $40.00, rating the stock as “outperform” in a report issued on December 16, 2025. Conversely, Wall Street Zen downgraded its rating from “hold” to “sell” on March 7, 2026.

Lake Street Capital also increased its target price from $22.00 to $32.00, giving the stock a “buy” rating. Weiss Ratings maintained a “sell (d-)” rating, while Craig Hallum raised its target from $33.00 to $36.00, also assigning a “buy” rating. Overall, ten analysts have rated Immunome as a “Buy,” with one rating it as a “Sell.” According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $33.45.

Immunome, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing innovative antibody-based therapeutics for oncology and infectious diseases. The company employs a proprietary platform to explore the natural B-cell repertoire of patients with active disease, identifying fully human monoclonal antibodies with unique mechanisms of action. Its lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.